Table 12.
Ongoing trials: Evaluating the use of RT for LMD.
| References | Study type | Study Pop/Pt treated with RT (n) | Treatment | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| H. Lee Moffitt Cancer Center (83) | Phase I | LMD | Arm 1: Avelumab + WBRT | NCT03719768 |
| Memorial Sloan Kettering (84) | Single arm, prospective | LMD | Proton CSI | NCT03520504 |
| The First Hospital of Jilin University Changchun, China (85) | Phase I/II | LMD from solid tumors | ITC (pemetrexed)+RT | NCT03507244 |
| The First Hospital of Jilin University Changchun, China (86) | Phase II | LMD from solid tumors | ITC (methotrexate and cytarabine)+RT | NCT03082144 |
| Memorial Sloan Kettering (87) | Phase I | LMD | I-131 monoclonal Ab RT | NCT00089245 |
RT, radiotherapy; LMD, leptomeningeal disease; Pop, population; Obs, observational study; PP, practice patterns; NR, not reported; BSC, best supportive care; C, chemotherapy alone; ITC, intrathecal chemotherapy; WBRT, whole brain radiotherapy; FSRT, spine RT; CSI, craniospinal RT.